L01FX25 • mosunetuzumab • Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates
Mosunetuzumabum is a monoclonal antibody used for the treatment of certain types of non-Hodgkin lymphoma, including relapsed or refractory follicular lymphoma. It works by activating T cells of the immune system to attack cancer cells.
The medication is administered via intravenous infusion and is used in cases where other treatments have failed. It is effective in reducing tumor size and prolonging patient survival.
Side effects may include cytokine release syndrome, fever, fatigue, nausea, and infections. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mosunetuzumabum. This medication must be administered under the supervision of an oncology specialist.
Substance: mosunetuzumab
Date of last drug list: 01-01-2026
Commercial code: W71595001
Concentration: 5mg
Pharmaceutical form: solution for injection
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ROCHE PHARMA AG - GERMANIA
Holder: ROCHE REGISTRATION GMBH - GERMANIA
Number: 1649/2022/03
Shelf life: 3 years - unopened bottle